BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35251021)

  • 1. Reactivity of NK Cells Against Ovarian Cancer Cells Is Maintained in the Presence of Calcium Phosphate Nanoparticles.
    Hrvat A; Schmidt M; Obholzer M; Benders S; Kollenda S; Horn PA; Epple M; Brandau S; Mallmann-Gottschalk N
    Front Immunol; 2022; 13():830938. PubMed ID: 35251021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.
    Gottschalk N; Kimmig R; Lang S; Singh M; Brandau S
    Int J Mol Sci; 2012; 13(9):12000-12016. PubMed ID: 23109896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
    Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
    Front Immunol; 2024; 15():1360615. PubMed ID: 38646521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells.
    Mallmann-Gottschalk N; Sax Y; Kimmig R; Lang S; Brandau S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma.
    Gong K; Dong Y; Wang L; Duan Y; Yu J; Sun Y; Bai M; Duan Y
    Int J Nanomedicine; 2020; 15():5561-5571. PubMed ID: 32801704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
    Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
    Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
    Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
    J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
    Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
    Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD137 enhances the efficacy of cetuximab.
    Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
    J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.
    Oppenheim DE; Spreafico R; Etuk A; Malone D; Amofah E; Peña-Murillo C; Murray T; McLaughlin L; Choi BS; Allan S; Belousov A; Passioukov A; Gerdes C; Umaña P; Farzaneh F; Ross P
    Br J Cancer; 2014 Mar; 110(5):1221-7. PubMed ID: 24496456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
    López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
    Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
    Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
    PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
    Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
    Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
    Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
    Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.